Table 3.
Previous studies | Year | ARTs | Gene-editing method | Recipient selection | Pregnancy rate (%) | Implantation rate (%) |
---|---|---|---|---|---|---|
Sun et al. (8) | 2008 | IVF, ICSI | None used | Synchronized recipients | 27.6 | 13.6 |
Liu et al. (5) | 2014 | IVF | TALEN | Synchronized recipients | 31.6 | 14.8 |
Niu et al. (3) | 2014 | ICSI | CRISPR/Cas9 | Synchronized recipients | 34.5 | 22.9 |
Wan et al. (4) | 2015 | ICSI | CRISPR/Cas9 | Synchronized recipients | 30.8 | 21.0 |
Seita et al. (47) | 2016 | ICSI | Lentivirus-mediated gene transfer | Not synchronized recipients | 66.7 | 60.0 |
Ke et al. (48) | 2016 | ICSI | TALEN | N.A. | 33.3 | 7.7 |
Zhao et al. (49) | 2017 | ICSI | CRISPR/Cas9 | N.A. | 8.1 | 2.6 |
Chen et al. (50) | 2017 | ICSI | TALEN | Synchronized recipients | 34.1 | 13.0 |
Zhang et al. (51) | 2018 | ICSI | CRISPR/Cas9 | Synchronized recipients | 33.3 | 8.3 |
Cui et al. (52) | 2018 | ICSI | CRISPR/Cas9 | Synchronized recipients | 30.0 | 13.3 |
Zhou et al. (53) | 2019 | ICSI | CRISPR/Cas9 | Synchronized recipients | 46.2 | 18.0 |
Qiu et al. (54) | 2019 | ICSI | CRISPR/Cas9 | Synchronized recipients | 32.3 | 9.1 |
Tsukiyama et al. (55) | 2019 | ICSI | CRISPR/Cas9 | Not synchronized recipients | 33.7 | N.A |
Huang et al. (19) | 2020 | ICSI | None used | Synchronized recipients | 25.0 | 27.3 |
Schmidt et al. (56) | 2020 | ICSI | CRISPR/Cas9 | Synchronized or not synchronized recipients | 0.0 | 0.0 |
Wang et al. (57) | 2020 | ICSI | CBE | Synchronized recipients | 54.5 | 19.5 |
Chen et al. (58) | 2021 | ICSI | CRISPR/Cas9 | Synchronized recipients | 24.0 | 13.7 |
Li et al. (59) | 2024 | FPNT | None used | Synchronized recipients | 20.0 | 11.4 |
Pregnancy rate = number of pregnant recipients/number of embryo-transferred recipients × 100; implantation rate = number of embryos implanted/number of embryos transferred × 100. CBE, cytosine base editing; CRISPR/Cas9, clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9; FPNT, female pronucleus transfer; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; N.A., not available; TALEN, transcription activator-like effector nuclease.